Keyphrases
Allogeneic
9%
Anti-tumor Response
9%
Antigen Loss
18%
Antigenic Modulation
9%
Autologous T Cell
9%
B-cell Malignancies
9%
Bone Marrow
9%
CD19
18%
CD19 Antigen
18%
CD19 chimeric Antigen Receptor T Cells
9%
CD19+
9%
CD3+
9%
Cell Manufacturing
9%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chimeric Antigen Receptor Therapy
9%
Customized Production
9%
Cytokine Production
9%
Direct Target
9%
Donor-derived
9%
Effector Cells
9%
Gamma delta
100%
Haploidentical Transplantation
9%
High Purity
9%
Independent Activity
100%
Leukemia
100%
Leukemia Cells
9%
Leukemic Cells
18%
Manufacturing Process
9%
Multiple Injections
9%
Oncohematology
9%
Oncologic Therapy
9%
Peripheral Blood Mononuclear Cells
9%
Production Process
9%
Remission Rate
9%
T Cells
45%
Target Antigen
9%
Transduction Efficacy
9%
Tumor Reduction
9%
Zoledronate
18%
Medicine and Dentistry
B Cell
12%
Cancer
12%
CD19 Antigen
25%
Cell Line
12%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor Immunotherapy
12%
Chimeric Antigen Receptor T-Cell
100%
Cytokine Production
12%
Effector Cell
12%
In Vitro
12%
Leukemia
100%
Leukemia Cell
12%
Neoplasm
25%
Oncology
12%
Peripheral Blood Mononuclear Cell
12%
Spine
12%
Spontaneous Remission
12%
T Cell
75%
T Cell Receptor
12%
Transplantation
12%
Zoledronic Acid
25%
Immunology and Microbiology
B Cell
12%
CD19
50%
CD19 Antigen
25%
CD3 Antigen
12%
Cell Line
12%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor T-Cell
100%
Cytokine Production
12%
Effector Cell
12%
Leukemia Cell
12%
Mouse
12%
Peripheral Blood Mononuclear Cell
12%
Solution and Solubility
12%
Spine
12%
T Cell
75%
T Cell Receptor
12%
Transplant Procedure
12%